Olema Oncology Statistics
Total Valuation
Olema Oncology has a market cap or net worth of $632.52 million. The enterprise value is $222.10 million.
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Olema Oncology has 87.61 million shares outstanding. The number of shares has increased by 18.41% in one year.
| Current Share Class | 87.61M |
| Shares Outstanding | 87.61M |
| Shares Change (YoY) | +18.41% |
| Shares Change (QoQ) | -3.22% |
| Owned by Insiders (%) | 2.68% |
| Owned by Institutions (%) | 96.58% |
| Float | 59.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.71 |
| P/TBV Ratio | 1.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.12, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.12 |
| Quick Ratio | 6.03 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -69.77% and return on invested capital (ROIC) is -46.18%.
| Return on Equity (ROE) | -69.77% |
| Return on Assets (ROA) | -39.82% |
| Return on Invested Capital (ROIC) | -46.18% |
| Return on Capital Employed (ROCE) | -67.98% |
| Weighted Average Cost of Capital (WACC) | 15.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.57M |
| Employee Count | 150 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.05% in the last 52 weeks. The beta is 2.02, so Olema Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 2.02 |
| 52-Week Price Change | -14.05% |
| 50-Day Moving Average | 8.04 |
| 200-Day Moving Average | 12.90 |
| Relative Strength Index (RSI) | 46.06 |
| Average Volume (20 Days) | 1,482,101 |
Short Selling Information
The latest short interest is 17.12 million, so 19.55% of the outstanding shares have been sold short.
| Short Interest | 17.12M |
| Short Previous Month | 15.68M |
| Short % of Shares Out | 19.55% |
| Short % of Float | 28.88% |
| Short Ratio (days to cover) | 12.85 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -252.77M |
| Pretax Income | -235.95M |
| Net Income | -235.95M |
| EBITDA | -252.27M |
| EBIT | -252.77M |
| Earnings Per Share (EPS) | -$2.40 |
Full Income Statement Balance Sheet
The company has $413.77 million in cash and $3.36 million in debt, with a net cash position of $410.42 million or $4.68 per share.
| Cash & Cash Equivalents | 413.77M |
| Total Debt | 3.36M |
| Net Cash | 410.42M |
| Net Cash Per Share | $4.68 |
| Equity (Book Value) | 368.84M |
| Book Value Per Share | 4.21 |
| Working Capital | 354.19M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$177.32 million and capital expenditures -$1.12 million, giving a free cash flow of -$178.44 million.
| Operating Cash Flow | -177.32M |
| Capital Expenditures | -1.12M |
| Depreciation & Amortization | 502,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -178.44M |
| FCF Per Share | -$2.04 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Olema Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -18.41% |
| Shareholder Yield | -18.41% |
| Earnings Yield | -33.25% |
| FCF Yield | -28.21% |
Analyst Forecast
The average price target for Olema Oncology is $35.50, which is 391.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.50 |
| Price Target Difference | 391.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |